Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672365 | 0.84 | ALOX5 (0.38) | TSHRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5675082 | 0.84 | ALDH1A1 (0.42) | TSHRPKMALDH1A1L3MBTL1PIM3 | |
| SCHEMBL5675093 | 0.82 | TSHR (0.41) | TSHRPKMALDH1A1L3MBTL1JAK2 | |
| SCHEMBL2336631 | 0.74 | TSHR (0.40) | TSHRPKMALDH1A1L3MBTL1CYP2C9 | |
| SCHEMBL11244583 | 0.72 | KDM4E (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL7839279 | 0.72 | NR4A2 (0.59) | TSHRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10717481 | 0.72 | TSHR (0.56) | TSHRPKMALDH1A1CYP2C9P2RX7 | |
| SCHEMBL15143986 | 0.72 | TSHR (0.40) | TSHRPKMALDH1A1L3MBTL1CYP2C9 | |
| SCHEMBL15143985 | 0.70 | TSHR (0.38) | TSHRPKMALDH1A1L3MBTL1JAK2 | |
| SCHEMBL7032023 | 0.68 | TSHR (0.71) | TSHRPKMALDH1A1L3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138424-B2 | Indole derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| CN-1234688-C | 3-aroyl indoles and their use as CB2Use of receptor agonists | SANOFI ANVANT (FR) | 2006-01-04 | — | — | CN | disclosed |
| EP-1507758-B1 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| EP-1507758-A2 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | Sanofi-Aventis (FR) | 2005-02-23 | — | — | EP | disclosed |
| CN-1483023-A | 3-arylindole derivatives and their use as cb2 receptor agonists | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-03-17 | — | — | CN | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| WO-2003097597-A2 | INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2003-11-27 | — | — | WO | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | TSHR 521/4885TUBB4A 2362/4885TUBB 2198/4885 |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | CNR2, CNR1, IDO2 | TSHR 838/4885TUBB4A 4131/4885TUBB 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.